Back to Newsroom

Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference

BERKELEY HEIGHTS, N.J., Feb. 06, 2018 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases, announced today that the Company will present at the 2018 BIO CEO Investor Conference being held February 12 & 13, 2018 at the New York Marriott Marquis, New York. Spiro Rombotis, President & Chief Executive Officer will provide an overview of the Company and its progress in key programs.